The relationship between inflammation, platelet activation and antiplatelet resistance

Inflammation and Allergy - Drug Targets

Volumn 9, Issue 5, 2010, Pages 364-381

  Acikel, Sadik ^a   Akdemir, Ramazan ^a  

^a MINISTRY OF HEALTH   (Turkey)

Author keywords

Aspirin resistance; Clopidogrel resistance; Inflammation; Platelets

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CLOPIDOGREL; HISTAMINE H2 RECEPTOR ANTAGONIST; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; THROMBOXANE A2;

ARTICLE; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESISTANCE; DRUG TARGETING; HUMAN; INFLAMMATION; NONHUMAN; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION;

EID: 79751499344     PISSN: 18715281     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152810793938017     Document Type: Article

References (129)

1. Konkle, B.A.; Simon, D.; Schafer, A.I. In: Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine; Libby, P.; Bonow, R.O.; Mann, D.L.; Zipes, D.P.; Braunwald, E., Eds.; Elsevier Saunders: Philadelphia, 2008, pp. 2049-2078.
2. Konkle, B.A. In: Harrison's Principles of Internal Medicine. Fauci, A.S.; Braunwald, E.; Kasper, D.L.; Hauser, S.L.; Longo, D.L.; Jameson, J.L.; Loscalzo, J., Eds.; McGraw-Hill Companies: United States of America, 2008, pp. 718-725.
3. Fitzgerald, D.J.; Maree, A. A spirin and clopidogrel resistance. Hematol. Am. Soc. Hematol. Educ. Program, 2007, 114-120.
4. Tantry, US.; Mahla, E.; Gurbel, P.A. Aspirin resistance. Prog. Cardiovasc. Dis., 2009, 52, 141-152.
5. Feher, G.; Feher, A.; Pusch, G.; Lupkovics, G.; Szapary, L.; Papp, E. The genetics of antiplatelet drug resistance. Clin. Genet., 2009, 75, 1-18.
6. Mason, P.J.; Jacobs, A.K.; Freedman, J.E. Aspirin resistance and atherothrombotic disease. J. Am. Coll. Cardiol., 2005, 46, 986-993.
7. Oqueli, E.; Hiscock, M.; Dick, R. Clopidogrel resistance. Heart Lung Circ., 2007, 16, 17-28.
8. Gawaz, M.; Langer, H.; May, A.E. Platelets in inflammation and atherogenesis. J. Clin. Invest., 2005, 115, 3378-3384.
9. Davì, G.; Patrono, C. Platelet activation and atherothrombosis. N. Engl. J. Med., 2007, 357, 2482-2494.
10. Esmon, C.T. Inflammation and thrombosis. J. Thromb. Haemost., 2003, 1, 1343-1348.
11. Vorchheimer, D.A.; Becker, R. Platelets in atherothrombosis. Mayo. Clin. Proc., 2006, 81, 59-68.
12. May, A.E.; Langer, H.; Seizer, P.; Bigalke, B.; Lindemann, S.; Gawaz, M. Platelet-leukocyte interactions in inflammation and atherothrombosis. Semin. Thromb. Hemost., 2007, 33, 123-127.
13. Jennings, L.K. Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis. Thromb. Haemost., 2009, 102, 248-257.
14. Steinhubl, S.R. Platelets as mediators of inflammation. Hematol. Oncol. Clin. N. Am., 2007, 21, 115-121.
15. Antoniades, C.; Bakogiannis, C.; Tousoulis, D.; Antonopoulos, A.S.; Stefanadis, C. The CD40/CD40 ligand system: linking inflammation with atherothrombosis. J. Am. Coll. Cardiol., 2009, 54, 669-677.
16. Yeh, E.T.; Khan, B.V. The potential role of antiplatelet agents in modulating inflammatory markers in atherothrombosis. J. Thromb. Haemost., 2006, 4, 2308-2316.
17. Muhlestein, J.B. Effect of antiplatelet therapy on inflammatory markers in atherothrombotic patients. Thromb. Haemost., 2010, 103, 71-82.
18. Duffy, B.; Bhatt, D.L. Antiplatelet agents in patients undergoing percutaneous coronary intervention: how many and how much? Am. J. Cardiovasc. Drugs., 2005, 5, 307-318.
19. Angiolillo, D.J.; Guzman, L.A.; Bass, T.A. Current antiplatelet therapies: benefits and limitations. Am. Heart J., 2008, 156, 3-9.
20. Guyer, K.E. The present state of aspirin and clopidogrel resistance. Hämostaseologie, 2009, 29, 285-290.
21. Hankey, G.J.; Eikelboom, J.W. Aspirin resistance. Lancet, 2006, 367, 606-617.
22. Gasparyan, A.Y.; Watson, T.; Lip, G.Y. The role of aspirin in cardiovascular protection. J. Am. Coll. Cardiol., 2008, 51, 1829-1843.
23. Kasotakis, G.; Pipinos, I.I.; Lynch, T.G. Current evidence and clinical implications of aspirin resistance. J. Vasc. Surg., 2009, 50, 1500-1510.
24. Cattaneo, M. Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler. Thromb. Vasc. Biol., 2004, 24, 1980-1987.
25. Altman, R.; Luciardi, HL.; Muntaner, J.; Herrera, RN. The antithrombotic profile of aspirin. Aspirin resistance, or simply failure? Thromb. J., 2004, 2, 1.
26. Wu, KK. Aspirin and salicylate: an old remedy with a new twist. Circulation, 2000, 102, 2022-2023.
27. Paul-Clark, M.J.; Van Cao, T.; Moradi-Bidhendi, N.; Cooper, D.; Gilroy, D.W. 15-epi-lipoxin A4-mediated induction of nitric oxide explains how aspirin inhibits acute inflammation. J. Exp. Med., 2004, 200, 69-78.
28. Fiorucci, S.; Distrutti, E.; Mencarelli, A.; Morelli, A.; Laufor, S.A.; Cirino, G.; Wallace, J.L. Evidence that 5-lipoxygenase and acetylated cyclooxygenase 2-derived eicosanoids regulate leukocyte-endothelial adherence in response to aspirin. Br. J. Pharmacol., 2003, 139, 1351-1359.
29. Smith, W.L. The eicosanoids and their biochemical mechanisms of action. Biochem. J., 1989, 259, 315-324.
30. FitzGerald, G.A.; Oates, J.A.; Hawiger, J.; Maas, R.L.; Roberts, L.J. 2nd.; Lawson, J.A.; Brash, A.R. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J. Clin. Invest., 1983, 71, 676-688.
31. Bala, M.; Chin, C.N.; Logan, A.T.; Amin, T.; Marnett, L.J.; Boutaud, O.; Oates, J.A. Acetylation of prostaglandin H2 synthases by aspirin is inhibited by redox cycling of the peroxidase. Biochem. Pharmacol., 2008, 75, 1472-1481.
32. Awtry, E.H.; Loscalzo, J. Aspirin. Circulation, 2000, 101, 1206-1218.
33. Undas, A.; Brummel-Ziedins, K.E.; Mann, K.G. Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions. Blood, 2007, 109, 2285-2292.
34. Chakraborty, K.; Khan, G.A.; Banerjee, P.; Ray, U.; Sinha, A.K. Inhibition of human blood platelet aggregation and the stimulation of nitric oxide synthesis by aspirin. Platelets, 2003, 14, 421-427.
35. Krayenbuehl, P.A.; Wiesli, P.; Schmid, M.; Schmid, C.; Ehses, J.A.; Hersberger, M.; Vetter, W.; Schulthess, G. TNF-alpha-308G>A polymorphism modulates cytokine serum concentrations and macrovascular complications in diabetic patients on aspirin. Exp. Clin. Endocrinol. Diabetes, 2007, 115, 322-326.
36. Cho, J.Y. Immunomodulatory effect of nonsteroidal antiinflammatory drugs (NSAIDs) at the clinically available doses. Arch. Pharm. Res., 2007, 30, 64-74.
37. Sugunaraj, J.P.; Palaniswamy, C.; Selvaraj, D.R.; Chaitanya, Arudra, S.K.; Sukhija, R. Clopidogrel resistance. Am. J. Ther., 2010, 17, 210-215.
38. Quinn M.J, Fitzgerald D.J. Ticlopidine and clopidogrel. Circulation, 1999, 100, 1667-1672.
39. Gurbel, P.A.; Tantry, U.S. The rationale for and comparisons of different antiplatelet treatments in acute coronary syndrome. J. Interv. Cardiol., 2008, 21, S10-7.
40. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet, 1988, 332, 349-360.
41. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ, 1994, 308, 81-106.
42. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ, 2002, 324, 71-86.
43. US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med., 2009, 150, 396-404.
44. Pignone, M.; Alberts, M.J.; Colwell, J.A.; Cushman, M.; Inzucchi, S.E.; Mukherjee, D.; Rosenson, R.S.; Williams, C.D.; Wilson, P.W.; Kirkman, M.S.; American Diabetes Association; American Heart Association; American College of Cardiology Foundation. Aspirin for primary prevention of cardiovascular events in people with diabetes. J. Am. Coll. Cardiol., 2010, 55, 2878-2886.
45. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet, 1996, 348, 1329-1339.
46. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med., 2001, 345, 494-502.
47. Beinart, S.C.; Kolm, P.; Veledar, E.; Zhang, Z.; Mahoney, E.M.; Bouin, O.; Gabriel, S.; Jackson, J.; Chen, R.; Caro, J.; Steinhubl, S.; Topol, E.; Weintraub, W.S. Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. J. Am. Coll. Cardiol., 2005, 46, 761-769.
48. Sabatine, M.S.; Cannon, C.P.; Gibson, C.M.; López-Sendón, J.L.; Montalescot, G.; Theroux, P.; Claeys, M.J.; Cools, F.; Hill, K.A.; Skene, A.M.; McCabe, C.H.; Braunwald, E.; CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N. Engl. J. Med., 2005, 352, 1179-1189.
49. Chen, Z.M.; Jiang, L.X.; Chen, Y.P.; Xie, J.X.; Pan, H.C.; Peto, R.; Collins, R.; Liu, L.S.; COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet, 2005, 366, 1607-1621.
50. Bhatt, D.L.; Fox, K.A.; Hacke, W.; Berger, P.B.; Black, H.R.; Boden, W.E.; Cacoub, P.; Cohen, E.A.; Creager, M.A.; Easton, J.D.; Flather, M.D.; Haffner, S.M.; Hamm, C.W.; Hankey, G.J.; Johnston, S.C.; Mak, K.H.; Mas, J.L.; Montalescot, G.; Pearson, T.A.; Steg, P.G.; Steinhubl, S.R.; Weber, M.A.; Brennan, D.M.; Fabry-Ribaudo, L.; Booth, J.; Topol, E.J.; CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N. Engl. J. Med., 2006, 354, 1706-1717.
51. Bhatt, D.L.; Flather, M.D.; Hacke, W.; Berger, P.B.; Black, H.R.; Boden, W.E.; Cacoub, P.; Cohen, E.A.; Creager, M.A.; Easton, J.D.; Hamm, C.W.; Hankey, G.J.; Johnston, S.C.; Mak, K.H.; Mas, J.L.; Montalescot, G.; Pearson, T.A.; Steg, P.G; Steinhubl, S.R.; Weber, M.A.; Fabry-Ribaudo, L.; Hu, T.; Topol, E.J.; Fox, K.A.; CHARISMA Investigators. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J. Am. Coll. Cardiol., 2007, 49, 1982-1988.
52. Grotemeyer, K.H.; Scharafinski, H.W.; Husstedt, I.W. Two-year follow-up of aspirin responder and aspirin non responder. A pilotstudy including 180 poststroke patients. Thromb. Res., 1993, 71, 397-403.
53. Eikelboom, J.W.; Hirsh, J.; Weitz, J.I.; Johnston, M.; Yi, Q.; Yusuf, S. Aspirin resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation, 2002, 105, 1650-1655.
54. Gum, P.A.; Kottke-Marchant, K.; Welsh, P.A.; White, J.; Topol, E.J. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J. Am. Coll. Cardiol., 2003, 41, 961-965.
55. Chen, W.H.; Lee, P.Y.; Ng, W.; Tse, H.F.; Lau, C.P. Aspirin resistance is associated with a high incidence of myonecrosis after nonurgent percutaneous coronary intervention despite clopidogrel pretreatment. J. Am. Coll. Cardiol., 2004, 43, 1122-1126.
56. Murphy, S.A.; Antman, E.M.; Wiviott, S.D.; Weerakkody, G.; Morocutti, G.; Huber, K.; Lopez-Sendon, J.; McCabe, C.H.; Braunwald, E.; TRITON-TIMI 38 Investigators. Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. Eur. Heart J., 2008, 29, 2473-2479.
57. Sofi, F.; Marcucci, R.; Gori, A.M.; Giusti, B.; Abbate, R.; Gensini, G.F. Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis. Thromb. Haemost., 2010, 103, 841-848.
58. Mangiacapra, F.; De Bruyne, B.; Muller, O.; Trana, C.; Ntalianis, A.; Bartunek, J.; Heyndrickx, G.; Di Sciascio, G.; Wijns, W.; Barbato, E. High residual platelet reactivity after clopidogrel: extent of coronary atherosclerosis and periprocedural myocardial infarction in patients with stable angina undergoing percutaneous coronary intervention. JACC. Cardiovasc. Interv., 2010, 3, 35-40.
59. Gasparyan, A.Y. Aspirin and clopidogrel resistance: methodological challenges and opportunities. Vasc. Health Risk Manag., 2010, 6, 109-112.
60. Wang, T.H.; Bhatt, D.L.; Topol, E.J. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur. Heart J., 2006, 27, 647-654.
61. Gurbel, P.A.; Becker, R.C.; Mann, K.G.; Steinhubl, S.R.; Michelson, A.D. Platelet function monitoring in patients with coronary artery disease. J. Am. Coll. Cardiol., 2007, 50, 1822-1834.
62. Harrison, P.; Frelinger, A.L. 3rd.; Furman, M.I.; Michelson, A.D. Measuring antiplatelet drug effect in the laboratory. Thromb. Res., 2007, 120, 323-336.
63. Angiolillo, D.J.; Suryadevara, S.; Capranzano, P.; Zenni, M.Z.; Guzman, L.A.; Bass, T.A. Antiplatelet drug response variability and the role of platelet function testing: a practical guide for interventional cardiologists. Catheter. Cardiovasc. Interv., 2009, 73, 1-14.
64. Braunwald, E.; Angiolillo, D.; Bates, E.; Berger, P.B.; Bhatt, D.; Cannon, C.P.; Furman, M.I.; Gurbel, P.; Michelson, A.D.; Peterson, E.; Wiviott, S. Assessing the current role of platelet function testing. Clin. Cardiol., 2008, 31, I36.
65. Michos, E.D.; Ardehali, R.; Blumenthal, R.S.; Lange, R.A.; Ardehali, H. Aspirin and clopidogrel resistance. Mayo. Clin. Proc., 2006, 81, 518-526.
66. Angiolillo, D.J. Variability in responsiveness to oral antiplatelet therapy. Am. J. Cardiol., 2009, 103, 27-34.
67. Maree, A.O.; Fitzgerald, D.J. Variable platelet response to aspirin and clopidogrel in atherothrombotic disease. Circulation, 2007, 115, 2196-2207.
68. Tourmousoglou, C.E; Rokkas, C.K. Clopidogrel and aspirin in cardiovascular medicine: responders or not-current best available evidence. Cardiovasc. Hematol. Agents Med. Chem., 2008, 6, 312-322.
69. Cattaneo, M. Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection. J. Thromb. Haemost., 2007, 5, 230-237.
70. Ford, N.F. Clopidogrel resistance: pharmacokinetic or pharmacogenetic? J. Clin. Pharmacol., 2009, 49, 506-512.
71. Angiolillo, D.J.; Fernandez-Ortiz, A.; Bernardo, E.; Alfonso, F.; Macaya, C.; Bass, T.A.; Costa, M.A. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J. Am. Coll. Cardiol., 2007, 49, 1505-1516.
72. Azam, S.M.; Jozic, J. Variable platelet responsiveness to aspirin and clopidogrel: role of platelet function and genetic polymorphism testing. Transl. Res., 2009, 154, 309-313.
73. Holmes, D.R. Jr.; Dehmer, G.J.; Kaul, S.; Leifer, D.; O'Gara, P.T.; Stein, C.M. ACCF/AHA clopidogrel clinical alert: approaches to the FDA boxed warning: a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J. Am. Coll. Cardiol., 2010, 56, 321-341.
74. Cyrus, T.; Sung, S.; Zhao, L.; Funk, C.D.; Tang, S.; Praticò, D. Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptordeficient mice. Circulation, 2002, 106:1282-1287.
75. Kodama, M.; Yamasaki, Y.; Sakamoto, K.; Yoshioka, R.; Matsuhisa, M.; Kajimoto, Y.; Kosugi, K.; Ueda, N.; Hori, M. Antiplatelet drugs attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes. Thromb. Res., 2000, 97, 239-245.
76. Redondo, S.; Santos-Gallego, C.G.; Ganado, P.; García, M.; Rico, L.; Del Rio, M.; Tejerina, T. Acetylsalicylic acid inhibits cell proliferation by involving transforming growth factor-β. Circulation, 2003, 107, 626-629.
77. Weber, C.; Erl, W.; Pietsch, A.; Weber, P.C. Aspirin inhibits nuclear factor kappa B mobilization and monocytes adhesion in stimulated human endothelial cells. Circulation, 1995, 91, 1914-1917.
78. Damås, J.K.; Waehre, T.; Yndestad, A.; Otterdal, K.; Hognestad, A.; Solum, N.O.; Gullestad, L.; Frøland, S.S.; Aukrust, P. Interleukin-7-mediated inflammation in unstable angina: possible role of chemokines and platelets. Circulation, 2003, 107, 2670-2676.
79. Ferroni, P.; Martini, F.; Cardarello, C.M.; Gazzaniga, P.P.; Davi, G.; Basili, S. Enhanced interleukin-1beta in hypercholesterolemia: effects of simvastatin and low-dose aspirin. Circulation, 2003, 108, 1673-1675.
80. Ikonomidis, I.; Andreotti, F.; Economou, E.; Stefanadis, C.; Toutouzas, P.; Nihoyannopoulos, P. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation, 1999, 100, 793-798.
81. Ridker, P.M.; Cushman, M.; Stampfer, M.J.; Tracy, R.P.; Hennekens, C.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N. Engl. J. Med., 1997, 336, 973-979.
82. Feng, D.; Tracy, R.P.; Lipinska, I.; Murillo, J.; McKenna, C.; Tofler, G.H. Effect of short-term aspirin use on C-reactive protein. J. Thromb. Thrombolysis, 2000, 9, 37-41.
83. Feldman, M.; Jialal, I.; Devaraj, S.; Cryer, B. Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: a placebo-controlled study using a highly sensitive C-reactive protein assay. J. Am. Coll. Cardiol., 2001, 37, 2036-2041.
84. Steinhubl, S.R.; Badimon, J.J.; Bhatt, D.L.; Herbert, J.M.; Lüscher, TF. Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease. Vasc. Med., 2007, 12, 113-122.
85. Quinn, M.J.; Bhatt, D.L.; Zidar, F.; Vivekananthan, D.; Chew, D.P.; Ellis, S.G.; Plow, E.; Topol, E.J. Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention. Am. J. Cardiol., 2004, 93, 679-684.
86. Azar, R.R.; Kassab, R.; Zoghbi, A.; Aboujaoudé, S.; El-Osta, H.; Ghorra, P.; Germanos, M.; Salamé, E. Effects of clopidogrel on soluble CD40 ligand and on high-sensitivity C-reactive protein in patients with stable coronary artery disease. Am. Heart J., 2006, 151, e1-4.
87. Saw, J.; Madsen, E.H.; Chan, S.; Maurer-Spurej, E. The ELAPSE (Evaluation of Long-Term Clopidogrel Antiplatelet and Systemic Anti-Inflammatory Effects) study. J. Am. Coll. Cardiol., 2008, 52, 1826-1833.
88. Gasparyan, A.Y. Inflammation, thrombosis and vascular biology: translating ideas into cardiovascular research and therapy. Open Cardiovasc. Med. J., 2010, 4, 20-22.
89. Gasparyan, A.Y.; Stavropoulos-Kalinoglou, A.; Mikhailidis, D.P.; Douglas, K.M.; Kitas, G.D. Platelet function in rheumatoid arthritis: arthritic and cardiovascular implications. Rheumatol. Int., 2010, Apr 14 [Epub ahead of print].
90. Yüksel, S.; Ayvazyan, L.; Gasparyan, A.Y. Familial mediterranean Fever as an emerging clinical model of atherogenesis associated with low-grade inflammation. Open. Cardiovasc. Med. J., 2010, 4, 51-56.
91. Zakynthinos, E.; Pappa, N. Inflammatory biomarkers in coronary artery disease. J. Cardiol., 2009, 53, 317-333.
92. Arazi, H.C.; Doiny, D.G.; Torcivia, R.S.; Grancelli, H.; Waldman, S.V.; Nojek, C.; Fornari, M.C.; Badimon, J.J. Impaired anti-platelet effect of aspirin, inflammation and platelet turnover in cardiac surgery. Interact. Cardiovasc. Thorac. Surg., 2010, 10, 863-867.
93. Guthikonda, S.; Lev, E.I.; Patel, R.; DeLao, T.; Bergeron, A.L.; Dong, J.F.; Kleiman, N.S. Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. J. Thromb. Haemost., 2007, 5, 490-496.
94. Narvaez, I.; Sagastagoitia, J.D.; Vacas, M.; Saez, Y.; Lafita, M.; Monica, S.; de Lafuente, J.P.; Molinero, E.; Iriarte, J.A. Prevalence and biologic profile of aspirin resistance in patients with angiographically proven coronary artery disease. Thromb. Res., 2007, 120, 671-677.
95. Markuszewski, L.; Rosiak, M.; Golanski, J.; Rysz, J.; Spychalska, M.; Watala, C. Reduced blood platelet sensitivity to aspirin in coronary artery disease: are dyslipidaemia and inflammatory states possible factors predisposing to sub-optimal platelet response to aspirin? Basic Clin. Pharmacol. Toxicol., 2006, 98, 503-509.
96. Acikel, S.; Yildirir, A.; Aydinalp, A.; Demirtas, K.; Bal, U.; Kaynar, G.; Ozin, B.; Karakayali, H.; Muderrisoglu, H.; Haberal, M. Incidence of aspirin resistance and its relationship with cardiovascular risk factors and graft function in renal transplant recipients. Transplant. Proc., 2008, 40, 3485-3488.
97. Acikel, S.; Yildirir, A.; Aydinalp, A.; Bal, U.; Kaynar, G.; Ozin, B.; Muderrisoglu, H. The clinical importance of laboratory-defined aspirin resistance in patients presenting with non-ST elevation acute coronary syndromes. Blood Coagul. Fibrinolysis, 2009, 20, 427-32.
98. Mateos-Cáceres, P.J.; Macaya, C.; Azcona, L.; Modrego, J.; Mahillo, E.; Bernardo, E.; Fernandez-Ortiz, A.; López-Farré, A.J. Different expression of proteins in platelets from aspirin-resistant and aspirin-sensitive patients. Thromb. Haemost., 2010, 103, 160-170.
99. Gori, A.M.; Cesari, F.; Marcucci, R.; Giusti, B.; Paniccia, R.; Antonucci, E.; Gensini, G.F.; Abbate, R. The balance between proand anti-inflammatory cytokines is associated with platelet aggregability in acute coronary syndrome patients. Atherosclerosis, 2009, 202, 255-262.
100. Gajos, G.; Rostoff, P.; Undas, A.; Piwowarska, W. Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: the OMEGA-PCI (OMEGA-3 fatty acids after pci to modify responsiveness to dual antiplatelet therapy) study. J. Am. Coll. Cardiol., 2010, 55, 1671-1678.
101. Acikel, S.; Akdemir, R.; Cagirci, G.; Yesilay, A.B.; Dogan, M.; Kilic, H. The treatment of clopidogrel resistance: Triple antiplatelet therapy and future directions. Int. J. Cardiol., 2010, 144, 79-82.
102. Gurbel, P.A.; Bliden, K.P.; DiChiara, J.; Newcomer, J.; Weng, W.; Neerchal, N.K.; Gesheff, T.; Chaganti, S.K.; Etherington, A.; Tantry, U.S. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation, 2007, 115, 3156-3164.
103. Lee, P.Y.; Chen, W.H.; Ng, W.; Cheng, X.; Kwok, J.Y.; Tse, H.F.; Lau, C.P. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. Am. J. Med., 2005, 118, 723-727.
104. Aydinalp, A.; Atar, I.; Altin, C.; Gülmez, O.; Atar, A.; Açikel, S.; Bozba, H.; Yildirir, A.; Müderrisolu, H. Platelet function analysis with two different doses of aspirin. Turk. Kardiyol. Dern. Ars., 2010, 38, 239-243.
105. ten Berg, J.M.; Gerritsen, W.B.; Haas, F.J.; Kelder, H.C.; Verheugt, F.W.; Plokker, H.W. High-dose aspirin in addition to daily low-dose aspirin decreases platelet activation in patients before and after percutaneous coronary intervention. Thromb. Res., 2002, 105, 385-390.
106. von Beckerath, N.; Taubert, D.; Pogatsa-Murray, G.; Schömig, E.; Kastrati, A.; Schömig, A. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation, 2005, 112, 2946-2950.
107. von Beckerath, N.; Kastrati, A.; Wieczorek, A.; Pogatsa-Murray, G.; Sibbing, D.; Graf, I.; Schömig, A. A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. Eur. Heart J., 2007, 28, 1814-1819.
108. Angiolillo, D.J.; Shoemaker, S.B.; Desai, B.; Yuan, H.; Charlton, R.K.; Bernardo, E.; Zenni, M.M.; Guzman, L.A.; Bass, T.A.; Costa, M.A. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation, 2007, 115, 708-716.
109. Fontana, P.; Senouf, D.; Mach, F. Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C19*2 allele on clopidogrel responsiveness. Thromb. Res., 2008, 121, 463-468.
110. Gladding, P.; Webster, M.; Zeng, I.; Farrell, H.; Stewart, J.; Ruygrok, P.; Ormiston, J.; El-Jack, S.; Armstrong, G.; Kay, P.; Scott, D.; Gunes, A.; Dahl, M.L. The antiplatelet effect of higher loading and maintenance dose regimens of clopidogrel: the PRINC (Plavix Response in Coronary Intervention) trial. JACC Cardiovasc. Interv., 2008, 1, 612-619.
111. Aleil, B.; Jacquemin, L.; De Poli, F.; Zaehringer, M.; Collet, J.P.; Montalescot, G.; Cazenave, J.P.; Dickele, M.C.; Monassier, J.P.; Gachet, C. Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator- Stimulated Phosphoprotein-02) randomized study. JACC Cardiovasc. Interv., 2008, 1, 631-638.
112. Palmerini, T.; Barozzi, C.; Tomasi, L.; Sangiorgi, D.; Marzocchi, A.; De Servi, S.; Ortolani, P.; Reggiani, L.B.; Alessi, L.; Lauria, G.; Bassi, M.; Branzi, A. A randomised study comparing the antiplatelet and antiinflammatory effect of clopidogrel 150 mg/day versus 75 mg/day in patients with ST-segment elevation acute myocardial infarction and poor responsiveness to clopidogrel: results from the DOUBLE study. Thromb. Res., 2010, 125, 309-314.
113. Price, M.J.; Coleman, J.L.; Steinhubl, S.R.; Wong, G.B.; Cannon, C.P.; Teirstein, P.S. Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers. Am. J. Cardiol., 2006, 98, 681-684.
114. Montalescot, G.; Sideris, G.; Meuleman, C.; Bal-dit-Sollier, C.; Lellouche, N.; Steg, P.G.; Slama, M.; Milleron, O.; Collet, J.P.; Henry, P.; Beygui, F.; Drouet, L.; ALBION Trial Investigators. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J. Am. Coll. Cardiol., 2006, 48, 931-938.
115. Di Sciascio, G.; Patti, G.; Pasceri, V.; Colonna, G.; Mangiacapra, F.; Montinaro, A. Clopidogrel reloading in patients undergoing percutaneous coronary intervention on chronic clopidogrel therapy: results of the ARMYDA-4 RELOAD (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) randomized trial. Eur. Heart J., 2010, 31, 1337-1343.
116. Dangas, G.; Mehran, R.; Guagliumi, G.; Caixeta, A.; Witzenbichler, B.; Aoki, J.; Peruga, J.Z.; Brodie, B.R.; Dudek, D.; Kornowski, R.; Rabbani, L.E.; Parise, H.; Stone, G.W.; HORIZONS-AMI Trial Investigators. Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: results from the HORIZONSAMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. J. Am. Coll. Cardiol., 2009, 54, 1438-1446.
117. Mehta, S.R.; Tanguay, J.F.; Eikelboom, J.W.; Jolly, S.S.; Joyner, C.D.; Granger, C.B.; Faxon, D.P.; Rupprecht, H.J.; Budaj, A.; Avezum, A.; Widimsky, P.; Steg, P.G.; Bassand, J.P.; Montalescot, G.; Macaya, C.; Di Pasquale, G.; Niemela, K.; Ajani, A.E.; White, H.D; Chrolavicius, S.; Gao, P.; Fox, K.A.; Yusuf, S.; CURRENTOASIS 7 trial investigators. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet, 2010, 376, 1233-1243.
118. Lee, S.W.; Park, S.W.; Hong, M.K.; Kim, Y.H.; Lee, B.K.; Song, J.M.; Han, K.H.; Lee, C.W.; Kang, D.H.; Song, J.K.; Kim, J.J.; Park, S.J. Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis. J. Am. Coll. Cardiol., 2005, 46, 1833-1837.
119. Angiolillo, D.J.; Capranzano, P.; Goto, S.; Aslam, M.; Desai, B.; Charlton, R.K.; Suzuki, Y.; Box, L.C.; Shoemaker, S.B.; Zenni, M.M.; Guzman, L.A.; Bass, T.A. A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. Eur. Heart J., 2008, 29, 2202-2211.
120. Jeong, Y.H.; Lee, S.W.; Choi, B.R.; Kim, I.S.; Seo, M.K.; Kwak, C.H.; Hwang, J.Y.; Park, S.W. Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study. J. Am. Coll. Cardiol., 2009, 53, 1101-1109.
121. Jeong, Y.H.; Hwang, J.Y.; Kim, I.S.; Park, Y.; Hwang, S.J.; Lee, S.W.; Kwak, C.H.; Park, S.W. Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study. Circ. Cardiovasc. Interv., 2010, 3, 17-26.
122. Serebruany, V.L.; Malinin, A.I.; Sane, D.C.; Jilma, B.; Takserman, A.; Atar, D.; Hennekens, C.H. Magnitude and time course of platelet inhibition with Aggrenox and Aspirin in patients after ischemic stroke: the AGgrenox versus Aspirin Therapy Evaluation (AGATE) trial. Eur. J. Pharmacol., 2004, 499, 315-324.
123. Gurbel, P.A.; Bliden, K.P.; Zaman, K.A.; Yoho, J.A.; Hayes, K.M.; Tantry, U.S. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation, 2005, 111, 1153-1159.
124. Cuisset, T.; Frere, C.; Quilici, J.; Morange, P.E.; Mouret, J.P.; Bali, L.; Moro, P.J.; Lambert, M.; Alessi, M.C.; Bonnet, J.L. Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study. JACC Cardiovasc. Interv., 2008, 1, 649-653.
125. Valgimigli, M.; Campo, G.; de Cesare, N.; Meliga, E.; Vranckx, P.; Furgieri, A.; Angiolillo, D.J.; Sabatè, M.; Hamon, M.; Repetto, A.; Colangelo, S.; Brugaletta, S.; Parrinello, G.; Percoco, G.; Ferrari, R. Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel (3T/2R) Investigators. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study. Circulation, 2009, 119, 3215-3222.
126. Yan, Y.; Phillips, D.R. Aspirin response and failure in diabetic patients with cardiovascular disease. Curr. Opin. Pharmacol., 2005, 5, 190-197.
127. Anfossi, G.; Russo, I.; Trovati, M. Platelet dysfunction in central obesity. Nutr. Metab. Cardiovasc. Dis., 2009, 19, 440-449.
128. Natarajan, A.; Zaman, A.G.; Marshall, S.M. Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents. Diab. Vasc. Dis. Res., 2008, 5, 138-144.
129. Angiolillo, D.J.; Suryadevara, S. Aspirin and clopidogrel: efficacy and resistance in diabetes mellitus. Best Pract. Res. Clin. Endocrinol. Metab., 2009, 23, 375-388.